Bellus Health gets new $4.10 price target at Mackie Research Capital

Jul 16 21:07 2019 Print This Article

Recent shifts in the competitive landscape have Mackie Research Capital analyst André Uddin raising his price target on Bellus Health (Bellus Health News, Stock Quote, Chart TSX:BLU). Uddin says in the landscape of chronic cough treatments, P2X3 inhibitors are showing the most promise and advanced class. “Four classes of treatments have been tested for chronic […]

The post Bellus Health gets new $4.10 price target at Mackie Research Capital appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Answers to popular stock and investing questions this week

This week we look at some of the most popular questions in the 5i Research question and answer service featuring Canopy Growth, Preferred Shares, and high interest savings accounts. ...

Profound Medical is ready for a breakout, says Mackie Research

Investors should soon expect a breakout for Profound Medical Corp (Profound Medical Corp Stock Quote, Chart, News TSX:PRN) after the company’s just-received FDA clearance for its TULSA-PRO medical device, says analyst Andre Uddin with Mackie Research Capital Corporation. The analyst provided an u ...

Canopy Growth Corp has lost its lead, GMP says

Following a quarter that came in softer than expected, GMP Securities analyst Ryan Macdonell has cut his price target on Canopy Growth Corp (Canopy Growth Corp Stock Quote, Chart, News TSX:WEED) On Wednesday, Canopy reported its Q1, 2020 results. The company lost $1.28-billion on net revenue of $90 ...

Canopy Growth Corp has price target slashed at PI

Canadian cannabis licensed producer Canopy Growth  (Canopy Growth  Corp Stock Quote, Chart, News TSE:WEED) got a big target price cut from PI Financial’s Jason Zandberg on the back of the company’s disappointing quarterly report. In an earnings update on Thursday, Zandberg kept his “Buy” ...

ProMetic Life Sciences has price target slashed at Echelon

Considerable losses and extended timelines for drug approval are keeping ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart, News TSX:PLI) a “Hold” for analyst Douglas Loe of Echelon Wealth Partners, who in a client update on Tuesday dropped his price target from $15.00 to $9.25 ...

Auxly Cannabis is making smart deals, this investor says

Looking for exposure in the pot sector that goes beyond the big names like Canopy Growth and Aurora? You might want to try cannabis streaming company and cultivator Auxly Cannabis (Auxly Cannabis Stock Quote, Chart, News TSXV:XLY), says portfolio manager Bruce Campbell, who commends the company’s ...

Acerus Pharmaceuticals has a 270 per cent upside, says Mackie Research

A supply shortage of the company’s nasal testosterone replacement therapy will impact sales estimates over the next two quarters but the end result is but a small hiccup for Acerus Pharmaceuticals (Acerus Pharmaceuticals Stock Quote, Chart, News TSX:ASP), according to Mackie Research’s André U ...

Buy Aphria for a double, GMP Securities says

Following Aphria’s (Aphria News, Stock Quote Chart TSX:APHA) first quarter results, GMP Securities is maintaining its “Buy” rating on Aphria, albeit with a new analyst at the helm. In the fourth quarter, Aphria posted net income of $15.8-million on net revenue of $128.6-million, a topline tha ...

Buy Aphria stock for a double, GMP Securities says

Following Aphria’s (Aphria News, Stock Quote Chart TSX:APHA) first quarter results, GMP Securities is maintaining its “Buy” rating on Aphria stock, albeit with a new analyst at the helm. In the fourth quarter, Aphria posted net income of $15.8-million on net revenue of $128.6-million, a topli ...

Buy CRH Medical for a double, Beacon Securities says

CRH Medical’s (CRH Medical News, Stock Quote, Chart TSX:CRH) second quarter results are a sneak peek at even better things to come says Beacon Securities analyst Doug Cooper. ON Wednesday, CRH reported its Q2, 2019 results. The company earned (US) $1.6-million on revenue of $30.5-million “Our 2 ...